The most widely used immune checkpoint blockade (ICB) therapeutic strategies target the PD-1/PD-L1 and CTLA4 axes to regulate anti-tumor immune activity with demonstrated clinical benefits [4]. This evidence concerns the gene CD274 and neoplasm.